La Jolla Pharmaceutical Company Announces U.S. FDA's Grant of Breakthrough Therapy Designation for LJPC-0118 for the Treatment of Severe Malaria

Stock Information for La Jolla Pharmaceutical Company

Loading

Please wait while we load your information from QuoteMedia.